
    
      A Phase 1, multicenter, dose escalation study of moxetumomab pasudotox (CAT-8015) in
      participants with relapsed or refractory hairy cell leukemia (HCL) to estimate the MTD,
      defined as the highest dose that can be safely administered to a patient, and to establish a
      safe dose, based on the MTD, for subsequent clinical testing (Phase 2 recommended dose).
    
  